Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database.
Lihong LiuYi ZhangMin ZhuLin FengYuhui ZhangZhuoling AnPublished in: Expert review of clinical pharmacology (2022)
Trastuzumab emtansine, trastuzumab deruxtecan and trastuzumab duocarmazine increased the risk of ILD, which can lead to serious outcomes and tends to occur early.
Keyphrases
- interstitial lung disease
- metastatic breast cancer
- systemic sclerosis
- epidermal growth factor receptor
- adverse drug
- clinical trial
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- drug induced
- tyrosine kinase
- emergency department
- randomized controlled trial
- type diabetes
- positive breast cancer
- cancer therapy
- adipose tissue
- phase iii
- skeletal muscle
- glycemic control